Pipeline

Debiopharm International’s projects cover all molecule type proteins,
peptides, small molecules

Discovery Preclinical Phase I Phase II Phase III
Head & Neck Cancer
IAP antagonist
Merck
NSCLC
IAP antagonist
Merck
Selected solid tumors
IAP antagonist
Merck
Selected solid tumors
IAP antagonist
Merck
Diffuse large B-cell lymphoma
Anti-CD37 ADC
ODD
Small cell lung cancer
Minigastrin-Lu177
Medullary thyroid cancer
Minigastrin-Lu177
Oncology
Wee1 kinase inhibitor
Oncology
CAIX-targeted radiotherapy
Oncology
IAP antagonist
Merck
ABSSSI
FabI inhibitor
FT/QIDP
Bone & joint infections
FabI inhibitor
ODD/FT/QIDP
Infectious diseases
Sample prep. Technology
SARS-CoV-2
Cyclophilin inhibitor
GI disorders
Cyclophilin inhibitor
N. gonorrhoeae
Fabl inhibitor
CARB-X
A. baumannii
Fabl inhibitor
CARB-X
GI disorders
microbiome remodeling
Takeda
*in combination with avelumab
**in combination with nivolumab
***in combination with pembrolizumab
ODD
Orphan Drug Designation
FT
Fast-Track
QIDP
Qualified Infectious Disease Product
BTD
Breakthrough Therapy Designation
CARB-X
CARB-X
Merck
Merck
Takeda
Takeda
Infectious disease
Oncology

Our commercialized products

Clinical trials

Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.

More about clinical trials